Demo Data from SIGIR 2026 / reviewers in the wild / expert
Edward A. Botchwey
dblp:78/6184
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2008
—ORCID · unresolved
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 2 heaviest of 3, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › drug discovery
drug mode of action analysis |
0.1 | 1 | 2008 | Novel pathway compendium analysis elucidates mechanism of pro-angiogenic synthetic small molecule · Bioinform. 2008 |
Bioinformatics and computational biology › systems bioinformatics
pathway analysis |
0.1 | 1 | 2008 | Novel pathway compendium analysis elucidates mechanism of pro-angiogenic synthetic small molecule · Bioinform. 2008 |
Methods — techniques the papers use, named apart from their topics
transcriptional regulatory footprint analysis · 0.1network analysis · 0.1microarray analysis · 0.1
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2008 | Novel pathway compendium analysis elucidates mechanism of pro-angiogenic synthetic small moleculeabstractAbstract Motivation: Computational techniques have been applied to experimental datasets to identify drug mode-of-action. A shortcoming of existing approaches is the requirement of large reference databases of compound expression profiles. Here, we developed a new pathway-based compendium analysis that couples multi-timepoint, controlled microarray data for a single compound with systems-based network analysis to elucidate drug mechanism more efficiently. Results: We applied this approach to a transcriptional regulatory footprint of phthalimide neovascular factor 1 (PNF1)—a novel synthetic small molecule that exhibits significant in vitro endothelial potency—spanning 1–48 h post-supplementation in human micro-vascular endothelial cells (HMVEC) to comprehensively interrogate PNF1 effects. We concluded that PNF1 first induces tumor necrosis factor-alpha (TNF-α) signaling pathway function which in turn affects transforming growth factor-beta (TGF-β) signaling. These results are consistent with our previous observations of PNF1-directed TGF-β signaling at 24 h, including differential regulation of TGF-β-induced matrix metalloproteinase 14 (MMP14/MT1-MMP) which is implicated in angiogenesis. Ultimately, we illustrate how our pathway-based compendium analysis more efficiently generates hypotheses for compound mechanism than existing techniques. Availability: The microarray data generated as part of this study are available in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). Contact: [email protected]; [email protected] Supplementary information: Supplementary data are available at Bioinformatics online. Kristen A. Wieghaus, Erwin P. Gianchandani, Mikell A. Paige, Milton L. Brown, Edward A. Botchwey, Jason A. Papin |
Bioinform. | 5 |